Trial · NCT06805968
Acute Exercise Intensity Responses in Women Who Smoke
NCT06805968, Not applicable, Completed, Istanbul Medipol University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acute Exercise Intensity Responses in Women Who Smoke. Trials, record NCT06805968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06805968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acute Exercise Intensity Responses in Women Who Smoke
- NCT number
- NCT06805968
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 30 participants, actual
- Lead sponsor
- Istanbul Medipol University Hospital
- Conditions
- Smokers
- Interventions
- High Intensity Exercise, Low Intensity Exercise
- First posted
- 2025-02-03
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate-Pressure Product (RPP) | Duration of change in 1 day. | Rate-pressure product (RPP) is calculated by multiplying heart rate (beats/min) by systolic blood pressure (mmHg) and dividing the result by 100. RPP provides an index of myocardial oxygen demand and cardiac workload. There is no fixed minimum or maximum value. Higher RPP values indicate greater myocardial workload and oxygen consumption. |
| Secondary | The Fagerström Test for Nicotine Dependence (FTND) | Duration of change in 1 day. | The Fagerström Test for Nicotine Dependence (FTND) is a 6-item questionnaire used to assess the level of nicotine dependence. Total scores range from 0 to 10, with higher scores indicating greater nicotine dependence. |
| Secondary | Cognitive status measurement with MOCA | Duration of change in 1 day. | The Montreal Cognitive Assessment (MoCA) is a screening tool used to assess global cognitive function, including attention, executive function, memory, language, visuospatial ability, abstraction, calculation, and orientation. Total scores range from 0 to 30, with higher scores indicating better cognitive function. |
| Secondary | Cognitive status measurement with Stroop Test | Duration of change in 1 day. | The Stroop Test assesses selective attention, cognitive flexibility, and inhibitory control. The primary outcome is the completion time (seconds) required to complete the interference condition. There is no fixed minimum or maximum value. Shorter completion times indicate better cognitive performance, whereas longer completion times indicate poorer cognitive performance. |
| Secondary | FEV1 Measurement | Duration of change in 1 day. | Respiratory Function Test. The COSMED microQuark spirometer used. Lung volume was evaluated. Forced Expiratory Volume in 1 Second (FEV₁) is measured using spirometry and represents the volume of air (liters) that can be forcibly exhaled during the first second of a forced expiration. There is no fixed minimum or maximum value. Higher FEV₁ values indicate better pulmonary function. |
| Secondary | FVC Measurement | Duration of change in 1 day. | Respiratory Function Test. The COSMED microQuark spirometer used. Lung volume was evaluated. Forced Vital Capacity (FVC) is measured using spirometry and represents the total volume of air (liters) that can be forcibly exhaled after a maximal inspiration. There is no fixed minimum or maximum value. Higher FVC values indicate better pulmonary function. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stroop Color-Word Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06805968
GET https://conductscience.org/api/trials/v1/NCT06805968/registered